<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685334</url>
  </required_header>
  <id_info>
    <org_study_id>#4696 (MH069868-01)</org_study_id>
    <secondary_id>1R21MH069868-01</secondary_id>
    <nct_id>NCT00685334</nct_id>
  </id_info>
  <brief_title>Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa</brief_title>
  <official_title>Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness of two atypical antipsychotic medications,
      olanzapine and aripiprazole, in treating people with anorexia nervosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anorexia nervosa (AN) is a disease of disordered eating that is characterized by
      self-starvation, often leading to extreme weight loss and difficulty maintaining a normal
      weight. Symptoms and behaviors of AN may include distorted body image, obsessive exercise,
      lack of menstruation among women, binge and purge eating behaviors, and intense fear of
      weight gain. Furthermore, people with AN are at a high risk of other mental disorders, such
      as depression and anxiety, and medical complications, such as organ damage, heart failure,
      and osteoporosis. Current treatments for AN include nutrition counseling, psychotherapy, and
      medication. Previous studies have suggested that certain medications usually used to treat
      schizophrenia, also known as atypical antipsychotic drugs, may be helpful in treating people
      with AN. Specifically, the atypical antipsychotic medications olanzapine and aripiprazole may
      be effective in improving overall symptoms of AN and in restoring weight to normal levels.
      This study will compare the effectiveness of olanzapine and aripiprazole in treating people
      with AN.

      Participation in this study will last 12 weeks. All participants will first undergo baseline
      assessments that will include questionnaires and interviews about AN symptoms, a physical
      exam, vital sign measurements, an electrocardiograph (EKG), and a blood draw. Participants
      will then be assigned randomly to 12 weeks of treatment with daily olanzapine or
      aripiprazole. Participants will meet with a study doctor weekly over the 12 weeks of
      treatment. During these visits, the study doctor will monitor participants' progress,
      medication dosage, vital signs, and side effects. In addition, participants will undergo
      repeat blood draws every 4 weeks and repeat questionnaires every month of the treatment
      period. Upon completing the 12 weeks of treatment, participants will repeat most baseline
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weight (Lbs.) at 12 Weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>This study looked at change in weight before and after medication use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>This study addressed the benefits, tolerability, acceptability, safety, and appropriate dosage of olanzapine and aripiprazole, as determined by clinical evaluation and self report. The outcome measure reported here is the number of patients who did not experience untoward side effects while taking the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication Side Effects</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>Common side effects include sedation, dizziness, and headache for patients on olanzapine and akathisia, anxiety, dizziness and blurred vision for patients receiving aripriprazole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>Total number of randomized patients that completed the full 12 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Eating Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Participants will take olanzapine daily for 12 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Participants will take aripiprazole daily for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for AN (DSM-IV criteria for amenorrhea will not be strictly
             applied, as these patients have been shown to be clinically indistinguishable from
             those with full criteria AN)

          -  Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2 (BMI of 19 is
             equivalent to approximately 85% of ideal body weight [IBW] according to Metropolitan
             Life standards, and BMI of 14 is equivalent to approximately 65% IBW)

          -  Unwilling to pursue inpatient treatment if BMI is less than 18 kg/m2

          -  Free of psychotropic (e.g., antidepressant, antianxiety, mood stabilizer,
             antipsychotic) medication for 2 weeks before study entry (free for 4 weeks before
             study entry if taking fluoxetine or antipsychotic medications)

          -  Prior treatment of AN

        Exclusion Criteria:

          -  Any medical or psychiatric problem requiring urgent clinical attention (e.g.,
             metabolic disturbance, acute suicidality) and/or significant comorbid illnesses that
             are not likely to benefit from proposed treatments

          -  Significant orthostatic high blood pressure (systolic change greater than 30 mmHg upon
             changing from supine to standing position)

          -  Allergy to olanzapine or aripiprazole

          -  Commencing psychotherapy in the community within 3 months of study entry

          -  Diabetes mellitus, with fasting serum glucose greater than 120 mg/dL or nonfasting
             serum glucose less than 140 mg/dL

          -  Known history of current or past jaundice

          -  Known history of narrow angle glaucoma

          -  Active substance abuse or dependence

          -  Schizophrenia, schizophreniform disorder, or bipolar illness

          -  Movement disorder or presence of tics

          -  History of tardive dyskinesia

          -  History of seizures

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Attia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute at Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.eatingdisordersclinic.org</url>
    <description>Click here for more information about this study at the Eating Disorders Research Clinic</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>August 3, 2009</results_first_submitted>
  <results_first_submitted_qc>January 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2010</results_first_posted>
  <last_update_submitted>September 25, 2013</last_update_submitted>
  <last_update_submitted_qc>September 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atypical Antipsychotics</keyword>
  <keyword>Anorexia Nervosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>Dosing of Olanzapine will begin at 2.5 mg and be increased every 2 weeks, first to 5 mg and then 10 mg, if the patient is tolerating the medication. Patients will remain on 10 mg for the final 8 weeks of the trial unless lower doses are necessary.</description>
        </group>
        <group group_id="P2">
          <title>Aripiprazole</title>
          <description>Aripiprazole dosing will begin at 5 mg daily, and will be increased every two weeks, first to 10 mg daily, then 15 mg daily for the final 8 weeks of the trial, unless lower doses are necessary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chose to enter hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>Dosing of Olanzapine will begin at 2.5 mg and be increased every 2 weeks, first to 5 mg and then 10 mg, if the patient is tolerating the medication. Patients will remain on 10 mg for the final 8 weeks of the trial unless lower doses are necessary.</description>
        </group>
        <group group_id="B2">
          <title>Aripiprazole</title>
          <description>Aripiprazole dosing will begin at 5 mg daily, and will be increased every two weeks, first to 10 mg daily, then 15 mg daily for the final 8 weeks of the trial, unless lower doses are necessary.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="7.2"/>
                    <measurement group_id="B2" value="30.7" spread="11.6"/>
                    <measurement group_id="B3" value="29.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight (Lbs.) at 12 Weeks</title>
        <description>This study looked at change in weight before and after medication use.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Dosing of Olanzapine will begin at 2.5 mg and be increased every 2 weeks, first to 5 mg and then 10 mg, if the patient is tolerating the medication. Patients will remain on 10 mg for the final 8 weeks of the trial unless lower doses are necessary.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole</title>
            <description>Aripiprazole dosing will begin at 5 mg daily, and will be increased every two weeks, first to 10 mg daily, then 15 mg daily for the final 8 weeks of the trial, unless lower doses are necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight (Lbs.) at 12 Weeks</title>
          <description>This study looked at change in weight before and after medication use.</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="6.3"/>
                    <measurement group_id="O2" value="-1.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability</title>
        <description>This study addressed the benefits, tolerability, acceptability, safety, and appropriate dosage of olanzapine and aripiprazole, as determined by clinical evaluation and self report. The outcome measure reported here is the number of patients who did not experience untoward side effects while taking the medication.</description>
        <time_frame>Measured at Week 12</time_frame>
        <population>Data was not available for all 22 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Dosing of Olanzapine will begin at 2.5 mg and be increased every 2 weeks, first to 5 mg and then 10 mg, if the patient is tolerating the medication. Patients will remain on 10 mg for the final 8 weeks of the trial unless lower doses are necessary.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole</title>
            <description>Aripiprazole dosing will begin at 5 mg daily, and will be increased every two weeks, first to 10 mg daily, then 15 mg daily for the final 8 weeks of the trial, unless lower doses are necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>This study addressed the benefits, tolerability, acceptability, safety, and appropriate dosage of olanzapine and aripiprazole, as determined by clinical evaluation and self report. The outcome measure reported here is the number of patients who did not experience untoward side effects while taking the medication.</description>
          <population>Data was not available for all 22 participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Side Effects</title>
        <description>Common side effects include sedation, dizziness, and headache for patients on olanzapine and akathisia, anxiety, dizziness and blurred vision for patients receiving aripriprazole.</description>
        <time_frame>Measured at Week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Compliance</title>
        <description>Total number of randomized patients that completed the full 12 weeks of treatment.</description>
        <time_frame>Measured at Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Dosing of Olanzapine will begin at 2.5 mg and be increased every 2 weeks, first to 5 mg and then 10 mg, if the patient is tolerating the medication. Patients will remain on 10 mg for the final 8 weeks of the trial unless lower doses are necessary.</description>
        </group>
        <group group_id="E2">
          <title>Aripiprazole</title>
          <description>Aripiprazole dosing will begin at 5 mg daily, and will be increased every two weeks, first to 10 mg daily, then 15 mg daily for the final 8 weeks of the trial, unless lower doses are necessary.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evelyn Attia, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>212-253-5923</phone>
      <email>ea12@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

